{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T23:24:47Z","timestamp":1785108287783,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Benign prostatic hyperplasia (BPH) is a leading cause of voiding symptoms in aging men. Telomerase reverse transcriptase (TERT), a key regulator of cellular senescence and tissue remodeling, has not been systematically examined in human voiding symptoms, though genome-wide association studies suggested a role in genetic and sporadic BPH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prostate tissues from patients undergoing laser enucleation for BPH were analyzed by RT-PCR. Clinical parameters were compared between TERT-positive and -negative patients. TERT expression in laser-enucleated tissues was tested for correlation with contractile smooth muscle receptors and the proliferation marker Ki67, and compared to tissues from radical prostatectomy for prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In a cohort of 100 patients undergoing laser enucleation of the prostate, we detected prostatic TERT mRNA in 81% of samples. Patients with TERT-positive tissues displayed clinically relevant higher symptom scores (22.5 vs. 17.4,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0407), and more pronounced post-void residual urine (80 vs. 142\u00a0ml). Prostate volume and free PSA showed no relationship with TERT expression. TERT expression correlated with expression of \u03b1\n                      <jats:sub>1A<\/jats:sub>\n                      -adrenoceptors (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), endothelin receptor A (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and B (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), thromboxane receptor (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), thromboxane synthase (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0050) and Ki67 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0181). TERT expression was 460-fold higher (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0015) in laser-enucleated than in periurethral prostatectomized tissues.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TERT expression associates with higher symptom severity in laser-enucleated BPH patients, and correlates with targets imparting drug resistance. We propose that TERT acts as a molecular switch, marking a clinically more severe BPH phenotype. This finding raises the possibility of targeted intervention in BPH patients with TERT-driven pathology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-025-06140-z","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T04:21:47Z","timestamp":1765426907000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["TERT expression in human prostate tissue reveals a potential molecular switch in benign prostatic hyperplasia progression"],"prefix":"10.1007","volume":"44","author":[{"given":"Yajie","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurenz","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Nicola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Weinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Tamalunas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian G.","family":"Stief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hennenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"6140_CR1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.euros.2024.10.012","volume":"70","author":"M Hennenberg","year":"2024","unstructured":"Hennenberg M, Hu S, Tamalunas A, Stief CG (2024) Genetic predisposition to benign prostatic hyperplasia: where do we stand? Eur Urol Open Sci 70:154\u2013157. https:\/\/doi.org\/10.1016\/j.euros.2024.10.012","journal-title":"Eur Urol Open Sci"},{"issue":"Suppl 9","key":"6140_CR2","first-page":"S3","volume":"6","author":"H Lepor","year":"2004","unstructured":"Lepor H (2004) Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol 6(Suppl 9):S3\u2013S10.","journal-title":"Rev Urol"},{"key":"6140_CR3","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","volume":"108","author":"DE Irwin","year":"2011","unstructured":"Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P (2011) Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 108:1132\u20131138. https:\/\/doi.org\/10.1111\/j.1464-410X.2010.09993.x","journal-title":"BJU Int"},{"key":"6140_CR4","doi-asserted-by":"publisher","unstructured":"Collaborators GBPH (2022) The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and. Lancet Healthy Longev 3:e754\u2013e76. https:\/\/doi.org\/10.1016\/s2666-7568(22)00213-6. Territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019","DOI":"10.1016\/s2666-7568(22)00213-6"},{"key":"6140_CR5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.eururo.2023.04.008","volume":"84","author":"S Gravas","year":"2023","unstructured":"Gravas S, Gacci M, Gratzke C, Herrmann TRW, Karavitakis M, Kyriazis I et al (2023) Summary paper on the 2023 European association of urology guidelines on the management of Non-neurogenic male lower urinary tract symptoms. Eur Urol 84:207\u2013222. https:\/\/doi.org\/10.1016\/j.eururo.2023.04.008","journal-title":"Eur Urol"},{"key":"6140_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0140-6736(20)31287-3","volume":"396","author":"G Magistro","year":"2020","unstructured":"Magistro G, Stief CG (2020) Surgery for benign prostatic obstruction. Lancet 396:5\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(20)31287-3","journal-title":"Lancet"},{"key":"6140_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/164_2023_678","volume":"285","author":"M Hennenberg","year":"2024","unstructured":"Hennenberg M, Michel MC (2024) Adrenoceptors in the lower urinary tract. Handb Exp Pharmacol 285:333\u2013367. https:\/\/doi.org\/10.1007\/164_2023_678","journal-title":"Handb Exp Pharmacol"},{"key":"6140_CR8","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1002\/nau.23557","volume":"37","author":"M Grabbert","year":"2018","unstructured":"Grabbert M, Buchner A, Butler-Ransohoff C, Kretschmer A, Stief CG, Bauer RM (2018) Long-term functional outcome analysis in a large cohort of patients after radical prostatectomy. Neurourol Urodyn 37:2263\u20132270. https:\/\/doi.org\/10.1002\/nau.23557","journal-title":"Neurourol Urodyn"},{"key":"6140_CR9","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s00345-024-05108-9","volume":"42","author":"T Westhofen","year":"2024","unstructured":"Westhofen T, Frank K, Buchner A, Becker A, Eismann L, Rodler S et al (2024) The impact of preoperative 5-alpha reductase inhibitors on functional outcomes and health-related quality of life following radical prostatectomy - A propensity score matched longitudinal study. World J Urol 42:432. https:\/\/doi.org\/10.1007\/s00345-024-05108-9","journal-title":"World J Urol"},{"key":"6140_CR10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.urology.2024.04.020","volume":"192","author":"T Westhofen","year":"2024","unstructured":"Westhofen T, Feyerabend E, Buchner A, Schlenker B, Becker A, Eismann L et al (2024) Impact of preoperative LUTS on Health-related quality of life following radical prostatectomy: A propensity score matched longitudinal study. Urology 192:52\u201358. https:\/\/doi.org\/10.1016\/j.urology.2024.04.020","journal-title":"Urology"},{"key":"6140_CR11","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.eururo.2008.11.011","volume":"55","author":"A Alcaraz","year":"2009","unstructured":"Alcaraz A, Hammerer P, Tubaro A, Schroder FH, Castro R (2009) Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol 55:864\u2013873. https:\/\/doi.org\/10.1016\/j.eururo.2008.11.011","journal-title":"Eur Urol"},{"key":"6140_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrurol.2012.192","volume":"10","author":"DD Orsted","year":"2013","unstructured":"Orsted DD, Bojesen SE (2013) The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol 10:49\u201354. https:\/\/doi.org\/10.1038\/nrurol.2012.192","journal-title":"Nat Rev Urol"},{"key":"6140_CR13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.urology.2023.08.020","volume":"182","author":"T Westhofen","year":"2023","unstructured":"Westhofen T, Buchner A, Eismann L, Rodler S, Keller P, Atzler M et al (2023) The impact of laser energy on functional outcome following holmium laser enucleation of the prostate. Urology 182:190\u2013195. https:\/\/doi.org\/10.1016\/j.urology.2023.08.020","journal-title":"Urology"},{"key":"6140_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.urology.2023.02.014","volume":"175","author":"A Tamalunas","year":"2023","unstructured":"Tamalunas A, Schott M, Keller P, Atzler M, Ebner B, Hennenberg M et al (2023) Efficacy, Efficiency, and safety of En-bloc vs Three-lobe enucleation of the prostate: A propensity Score-matched analysis. Urology 175:48\u201355. https:\/\/doi.org\/10.1016\/j.urology.2023.02.014","journal-title":"Urology"},{"key":"6140_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/luts.12404","volume":"14","author":"A Tamalunas","year":"2022","unstructured":"Tamalunas A, Westhofen T, Schott M, Keller P, Atzler M, Stief CG et al (2022) Holmium laser enucleation of the prostate: A truly size-independent method? Low Urin Tract Symptoms 14:17\u201326. https:\/\/doi.org\/10.1111\/luts.12404","journal-title":"Low Urin Tract Symptoms"},{"key":"6140_CR16","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/s0022-5347(17)36966-5","volume":"148","author":"MJ Barry","year":"1992","unstructured":"Barry MJ, Fowler FJ Jr., O\u2019Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK et al (1992) The American urological association symptom index for benign prostatic hyperplasia. The measurement committee of the American urological association. J Urol 148:1549\u20131557 discussion 64. https:\/\/doi.org\/10.1016\/s0022-5347(17)36966-5","journal-title":"J Urol"},{"key":"6140_CR17","doi-asserted-by":"publisher","unstructured":"Pradidarcheep W, Wallner C, Dabhoiwala NF, Lamers WH (2011) Anatomy and histology of the lower urinary tract. https:\/\/doi.org\/10.1007\/978-3-642-16499-6_7. Handb Exp Pharmacol:117\u2009\u2013\u200948","DOI":"10.1007\/978-3-642-16499-6_7"},{"key":"6140_CR18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3892\/mmr.2011.647","volume":"5","author":"Z Shaikhibrahim","year":"2012","unstructured":"Shaikhibrahim Z, Lindstrot A, Ellinger J, Rogenhofer S, Buettner R, Perner S et al (2012) The peripheral zone of the prostate is more prone to tumor development than the transitional zone: is the ETS family the key? Mol Med Rep 5:313\u2013316. https:\/\/doi.org\/10.3892\/mmr.2011.647","journal-title":"Mol Med Rep"},{"key":"6140_CR19","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.1038\/s41598-025-88884-7","volume":"15","author":"P Keller","year":"2025","unstructured":"Keller P, Hu S, Berger L, Nicola P, Schierholz F, Tamalunas A et al (2025) Smooth muscle contractility of laser-enucleated prostate tissues and impacts of preoperative alpha(1)-blocker treatment in patients with and without catheterization. Sci Rep 15:4985. https:\/\/doi.org\/10.1038\/s41598-025-88884-7","journal-title":"Sci Rep"},{"key":"6140_CR20","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/s0022-5347(01)66780-6","volume":"154","author":"MJ Barry","year":"1995","unstructured":"Barry MJ, Williford WO, Chang Y, Machi M, Jones KM, Walker-Corkery E et al (1995) Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American urological association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 154:1770\u20131774. https:\/\/doi.org\/10.1016\/s0022-5347(01)66780-6","journal-title":"J Urol"},{"key":"6140_CR21","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.1038\/s41598-025-88884-7","volume":"15","author":"P Keller","year":"2025","unstructured":"Keller P, Hu S, Berger L, Nicola P, Schierholz F, Tamalunas A et al (2025) Smooth muscle contractility of laser-enucleated prostate tissues and impacts of preoperative \u03b1(1)-blocker treatment in patients with and without catheterization. Sci Rep 15:4985. https:\/\/doi.org\/10.1038\/s41598-025-88884-7","journal-title":"Sci Rep"},{"key":"6140_CR22","doi-asserted-by":"publisher","first-page":"1612954","DOI":"10.3389\/fphys.2025.1612954","volume":"16","author":"P Keller","year":"2025","unstructured":"Keller P, Hu S, Nicola P, Berger L, Tamalunas A, Weinhold P et al (2025) Voiding symptom severity varies independently from non-adrenergic prostate smooth muscle contractions in patients undergoing surgery for benign prostatic hyperplasia. Front Physiol 16:1612954. https:\/\/doi.org\/10.3389\/fphys.2025.1612954","journal-title":"Front Physiol"},{"key":"6140_CR23","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.eururo.2014.01.007","volume":"66","author":"R Cartwright","year":"2014","unstructured":"Cartwright R, Mangera A, Tikkinen KA, Rajan P, Pesonen J, Kirby AC et al (2014) Systematic review and meta-analysis of candidate gene association studies of lower urinary tract symptoms in men. Eur Urol 66:752\u2013768. https:\/\/doi.org\/10.1016\/j.eururo.2014.01.007","journal-title":"Eur Urol"},{"key":"6140_CR24","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1038\/s41467-018-06920-9","volume":"9","author":"J Gudmundsson","year":"2018","unstructured":"Gudmundsson J, Sigurdsson JK, Stefansdottir L, Agnarsson BA, Isaksson HJ, Stefansson OA et al (2018) Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA. Nat Commun 9:4568. https:\/\/doi.org\/10.1038\/s41467-018-06920-9","journal-title":"Nat Commun"},{"key":"6140_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S1016-8478(23)13173-6","volume":"19","author":"YH Sung","year":"2005","unstructured":"Sung YH, Choi YS, Cheong C, Lee HW (2005) The Pleiotropy of telomerase against cell death. Mol Cells 19:303\u2013309.","journal-title":"Mol Cells"},{"key":"6140_CR26","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.eururo.2015.09.039","volume":"69","author":"JK Rane","year":"2016","unstructured":"Rane JK, Greener S, Frame FM, Mann VM, Simms MS, Collins AT et al (2016) Telomerase activity and telomere length in human benign prostatic hyperplasia Stem-like cells and their progeny implies the existence of distinct basal and luminal cell lineages. Eur Urol 69:551\u2013554. https:\/\/doi.org\/10.1016\/j.eururo.2015.09.039","journal-title":"Eur Urol"},{"key":"6140_CR27","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/ncb3047","volume":"16","author":"CW Chua","year":"2014","unstructured":"Chua CW, Shibata M, Lei M, Toivanen R, Barlow LJ, Bergren SK et al (2014) Single luminal epithelial progenitors can generate prostate organoids in culture. Nat Cell Biol 16:951\u2013961. https:\/\/doi.org\/10.1038\/ncb3047","journal-title":"Nat Cell Biol"},{"key":"6140_CR28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41585-021-00561-2","volume":"19","author":"M Baures","year":"2022","unstructured":"Baures M, Dariane C, Tika E, Puig Lombardi E, Barry Delongchamps N, Blanpain C et al (2022) Prostate luminal progenitor cells: from mouse to human, from health to disease. Nat Rev Urol 19:201\u2013218. https:\/\/doi.org\/10.1038\/s41585-021-00561-2","journal-title":"Nat Rev Urol"},{"key":"6140_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.diff.2017.07.005","volume":"96","author":"DW Strand","year":"2017","unstructured":"Strand DW, Costa DN, Francis F, Ricke WA, Roehrborn CG (2017) Targeting phenotypic heterogeneity in benign prostatic hyperplasia. Differentiation 96:49\u201361. https:\/\/doi.org\/10.1016\/j.diff.2017.07.005","journal-title":"Differentiation"},{"key":"6140_CR30","doi-asserted-by":"publisher","unstructured":"Plyasova AA, Zhdanov DD (2021) Alternative splicing of human telomerase reverse transcriptase (hTERT) and its implications in physiological and pathological processes. https:\/\/doi.org\/10.3390\/biomedicines9050526. Biomedicines 9","DOI":"10.3390\/biomedicines9050526"},{"key":"6140_CR31","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.1038\/s41388-019-0872-9","volume":"38","author":"X Yuan","year":"2019","unstructured":"Yuan X, Larsson C, Xu D (2019) Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. Oncogene 38:6172\u20136183. https:\/\/doi.org\/10.1038\/s41388-019-0872-9","journal-title":"Oncogene"},{"key":"6140_CR32","doi-asserted-by":"publisher","unstructured":"Kamradt J, Drosse C, Kalkbrenner S, Rohde V, Lensch R, Lehmann J et al (2003) Telomerase activity and telomerase subunit gene expression levels are not related in prostate cancer: a real-time quantification and in situ hybridization study. Laboratory investigation; a journal of technical methods and pathology 83:623\u2009\u2013\u200933. https:\/\/doi.org\/10.1097\/01.lab.0000069035.85309.30","DOI":"10.1097\/01.lab.0000069035.85309.30"},{"key":"6140_CR33","first-page":"4803","volume":"6","author":"V Rohde","year":"2000","unstructured":"Rohde V, Sattler HP, Bund T, Bonkhoff H, Fixemer T, Bachmann C et al (2000) Expression of the human telomerase reverse transcriptase is not related to telomerase activity in normal and malignant renal tissue. Clin Cancer Res 6:4803\u20134809.","journal-title":"Clin Cancer Res"},{"key":"6140_CR34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41419-024-06454-7","volume":"15","author":"M Liu","year":"2024","unstructured":"Liu M, Zhang Y, Jian Y, Gu L, Zhang D, Zhou H et al (2024) The regulations of telomerase reverse transcriptase (TERT) in cancer. Cell Death Dis 15:90. https:\/\/doi.org\/10.1038\/s41419-024-06454-7","journal-title":"Cell Death Dis"},{"key":"6140_CR35","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3389\/fcell.2019.00332","volume":"7","author":"E S\u00e9gal-Bendirdjian","year":"2019","unstructured":"S\u00e9gal-Bendirdjian E, Geli V (2019) Non-canonical roles of telomerase: unraveling the imbroglio. Front Cell Dev Biol 7:332. https:\/\/doi.org\/10.3389\/fcell.2019.00332","journal-title":"Front Cell Dev Biol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-06140-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-06140-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-06140-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T04:21:48Z","timestamp":1765426908000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-06140-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6140"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-06140-z","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was carried out in accordance with the Declaration of Helsinki of the World Medical Association and has been approved by the ethics committee of the Ludwig-Maximilians University, Munich, Germany (approval number 22\u20130608, from 08\u201310\u20132022).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Informed consent was obtained from all individual participants included in the study. Samples and data were collected and analyzed pseudonymized.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}],"article-number":"33"}}